[Alpha Biz=(Chicago) Reporter Kim Jisun] Daewoong Pharmaceutical succeeded in localizing diabetes treatments of the SGLT-2 (sodium glucose cotransporter 2, Sodium-glucose Joint Transporter 2) inhibitors.
Daewoong Pharmaceutical made an announcement on the 1st that its 36th domestic new drug, Enblo tablet 0.3mg (Seong Myung-myung: Inabogliflozin), will be released in South Korea after receiving insurance benefits for diabetes solvents.
According to Daewoong Pharmaceutical, Enblojeong confirmed its effectiveness and safety with a dose of 0.3mg, which is less than one-third of the existing SGLT-2 inhibitors.
The SGLT-2 inhibitor-based diabetes drug is regarded as the world's next leading diabetes treatment not only for its blood sugar reduction effect, but also for its cardiovascular and kidney disease benefits, as well as weight loss and blood pressure reduction effects. If existing diabetes drugs promoted insulin secretion or prevented insulin decomposition, SGLT-2 inhibitors are a new mechanism to excrete glucose in the urine and were found to be effective when used in combination with other drugs.
Daewoong Pharmaceutical plans to actively inform domestic medical staff of the special features of Enblock, which was developed with its own technology.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
